

CURRICULUM VITAE

ALAN PAUL GLOMBICKI, M.D.

ADDRESS: 5031 Braesheather Drive
Houston, Texas 77096

BIRTH: March 4, 1956
Chicago, Illinois

EDUCATION: Massachusetts Institute of Technology
Bachelor of Science, Biology/Chemical Engineering
June, 1977

University of Illinois School of Medicine
Doctor of Medicine
June 1981

POSTGRADUATE TRAINING AND APPOINTMENTS

2012- Present, Treasurer Houston Academy of Medicine/ Harris County Executive Board

2012-Director, Motility and Endoscopy, First Street Surgical Center

2009-present Representative to the Egyptian Hepatoma Screening Program, AASLD

2009- M of Health Steering Committee, Abu Dhabi, Bahrain Hepatitis Symposia

2008- Visiting Lecturer, Emirates Gastroenterology Association

2008-2000- Infectious Disease Committee Staff Member, Texas Medical Association

2007-present National Policy Board, AASLD

2007- GI Emissary to Minister of Health, United Arab Emirates, Dubai TMH

2006-Poster Presentation, International Association for Study Liver Diseases, Cairo

2006-Council on Legislative Affairs, Harris County Medical Society

10/02-12/05 -Liver Clinic Director, Hepatology/GI MD Anderson Hospital

2004-2002- Utilization Committee, Tenet Medical Systems

2004-1999-Founding President, American Liver Foundation of Texas

2004-Vice-President, Harris County Medical Society

6/2003 –present, Associate Professor of Clinical Medicine, Liver Transplant Unit Gastroenterology Section University of Texas Medical School, Houston

6/2003 –6/1989, Assistant Professor of Clinical Medicine, Liver Transplant Unit Gastroenterology Section University of Texas Medical School, Houston

2003-Secretary-Treasurer, Harris County Medical Society

2003- Board of Directors, Harris County Med Society / Houston Academy of Medicine

2001-present- Delegate, Texas Medical Association,

2001-2000- President/Central Branch, Board of Directors, Harris County Medical Society

6/98- Tenet Medical Staff Delegate, American Medical Association

10/97 - Chairman of AMA Mini-Internship, Harris County Medical Society

6/97 - Houston Central Branch Delegate, American Medical Association

1997-96 - President, Houston Gastroenterology Society

1996/1995 - Advanced Closed Circuit Endoscopic Surgery (ACES) Course Co-Director,
MD Anderson Cancer Center/ UT Houston

10/94- Presentation of Interactive Video Laser Disc Patient Education Program for Colorectal Cancer Screening, European Congress of Gastroenterology, Berlin

6/94- Exhibitor, European Congress of Gastroenterology, Oslo

7/93- Exhibitor European Congress of Gastroenterology, Barcelona

9/92- Exhibitor/ Poster Session, European Congress of Gastroenterology, Athens

1992-Reviewer for Annals of Internal Medicine & Journal of American College of GI

7/91-Plenary Session Faculty: Drugs and Liver Transplantation, Lorenzini Foundation
Milan

POSTGRADUATE TRAINING AND APPOINTMENTS

2/91- AGA Specialized Post-Graduate Preceptorship in Liver Transplantation. University of Nebraska Medical Center. Omaha

1/91 -Masters in Public Health Program University Texas Health Science Center, Houston

6/91-6/89-Medical Director, Liver Transplant Unit, The Methodist Hospital/Baylor College of Medicine. Houston

9/91- 3/89-Co-Principal Investigator, Extracorporeal Shock Wave Lithotripsy/Biliary Facility, The Methodist Hospital, Houston

1/90-Protocol Review Auditor, General Clinical Review Center, The Methodist Hospital. Houston

6/89- 7/87-Instructor in Medicine, Gastroenterology Section, Baylor College of Medicine, Houston

10/88- Therapeutic Biliary Endoscopy, Duke University

8/88- Extracorporeal Shock Wave Biliary Lithotripsy Preceptorship, Technomed International, Inc. Hospital St. Joseph, Paris

5/87-ASGE Endoscopy Data Based Tutorial at the MUMPS Medical Information Systems (MMIMS) Headquarters, Dr. Daniel Kruss, Heinz VA, Maywood Illinois

6/87-7/86- N.I.H. Clinical Research Fellowship in Transplant Hepatology. The Methodist Hospital Baylor College of Medicine, Section of Gastroenterology. Houston

11/86- Orthotopic Liver Transplant Management Course, University of Pittsburgh

6/86-7/84-Fellowship in Gastroenterology, Baylor Affiliated Hospitals, Houston

6/84- 7/81-Categorical Internal Medicine Internship and Residency. Baylor Affiliated Hospitals, Houston

RESEARCH AFFILIATIONS:

2013 - Present
Cure C Consortium
Sub Investigator
4900 Fannin St.
Houston, TX 77004

SPECIALTY SKILLS

Combination Anti-viral Chemotherapy with Colony Stimulating Factors, Evaluation, Pre-Operative and Post-Operative Management of Liver Transplant Candidates, Panendoscopy, Colonoscopy, E.R.C.P., Polypectomy, Pneumatic and Standard Dilatation, Coagulation Therapy, Sclerotherapy, Endoscopic Gastrostomy, Laparoscopy Liver Biopsy, Esophageal Manometry, Gastric Analysis, Hyperalimentation, Endoscopic Papillotomy, Biliary Stent Placement, Extra- Corporeal Shock Wave Lithotripsy, Nutritional Support, heater Probe/Argon Plasma Coagulation, and pH Monitoring Gastroenterology Section Database Syscom on dBase III, Member of HAL-PC

PRACTICE EXPERIENCE

3/96-present Houston Digestive Diseases Consultants

7/91-2/96-Staff Gastroenterologist/Hepatologist, Mac Gregor Clinic, Houston

4/84 6/87-Emergency Physicians PA, Del Oro Hospital, Houston

4/84-9/87-Emergency Room, House Physician, Sharpstown General Hospital, Houston

5/83-6/84-Receiving Clinic, House Physician, Houston Veteran's Hospital

10/82 4/84-Intensive Care Unit, House Physician. St. Luke's Hospital, Houston

10/79-6/81 -Occupational Health Staff, Ryerson Steel Corporation, Chicago

AWARDS AND HONORS

5/91-Academic Exhibits 2nd Place Prize, Computer Video laser Disc MacTransplant, Texas Medical Association, Dallas

7/86-6/87- N.I.H. Research Fellowship in Hepatology and Liver Transplantation, Baylor College of Medicine, Houston

1981- Senior Leadership Award, University of Illinois School of Medicine, Chicago

8/77 – Sigma Xi Scientific Research Award, Massachusetts Institute of Technology, Boston

PUBLICATIONS

Glombicki, A., Fadem, S. (1995) Colorectal Cancer Screening Compliance Enhanced by Personal Computer (PC) Based Multimedia Patient Education. Gut, 37(2): A257.

Potts, J., Stephen, A., Glombicki, A. (1992) Nutritional Management of Chronic Liver Failure. Postgraduate General Surgery, 4(4): 253.

Munzer, D., Glombicki, A. (1992) Limitations and insufficiency of endoscopy in evaluating mechanical dysphagia in non oesophageal organic diseases (a study of 15 cases) Hellenic Journal of Gastroenterology, Volume 5 Supplement, 237:948.

Opekun, A. R., Klein, P.D., Whisennand, H. H., Glombicki, A. P., Sekely, S. L., Graham, D. Y.. (1991) 13-Caminopyrine Breath Test Used in Evaluation of the Perioperative Liver Transplant Patient. Gastroenterology, 100(3).

Stroehlein, J. R., Barroso, A., Glombicki, A. P., Sachs, I. (1990) Documentation of Fluoroscopic and Endoscopic Images Using a Color Video Printer. Gastrointestinal Endoscopy, 36(4): 392.

Ferry, G. D., Whisennand, H. H., Finegold, M. J., Alpert, E., Glombicki, A., (1990) The Successful Treatment of Cholesterol Ester Storage Disease by Liver Transplantation. Journal of Pediatric Gastroenterology and Nutrition.

Glombicki, A.P., Haber, L., Whisennand, H., Moake, J., McPerson, P. (1990) Successful Treatment of Heterozygous Protein-C Deficiency. Hepatology, 10(4): 661.

Glombicki, A., Long, K., Paul, J., Young, J., DeBakey, M. (1989) Interactive Computer Laser Video Disc Module for Teaching Liver Transplant Immunosuppression. Hepatology. 10(4):661.

Glombicki, A. P., Alpert, E., Nelson, D.L., Young, J. B., Short, H. D., III, Whisennand, H. H., Noon, G. P. DeBakey, M. E., and Lawrence, E. C., (1987). The Prognostic Significance of Soluble Interleukin-2 Receptor Levels in Human Serum Following Orthotopic Liver Transplantation. Gastroenterology. 92(5): 1736.

Glombicki, A. P. and Smith J. L. (1987) Diagnosis: Lower Gastrointestinal Hemorrhage. Hospital Practice, 21 - 39.

RESEARCH INTERESTS

Antiviral Combination Chemotherapy for Chronic Hepatitis, Magnetic Resonance Imaging in Diabetic Steatosis. Kupffer Cell Population Kinetics in Orthotopic Liver Transplants. IL-2R Levels in Episodes of Liver Transplant Rejection. Stable Isotope Breath Testing of Quantitative Liver Function After Liver Transplantation. Cost-Benefit Analysis of Colon Cancer Screening Using Computer Simulation Models. Biliary Lithotripsy.

BOOK CHAPTERS

Hepatitis A Virus, (1383-1399), Principles and Practice of Infectious Diseases, Ed. Mandell, Douglas, Bennett;, Churchill Livingstone, New York, 3rd. Edition, 1990.

PROFESSIONAL SOCIETY MEMBERSHIPS

American Association for the Study of Liver Diseases, American Medical Informatics Association Fellow, American College of Physicians Fellow, American College of Gastroenterology Fellow, American Society for Gastrointestinal Endoscopy American Gastroenterology Association American Diabetes Association Harris County Medical Society Texas Endoscopists Society Houston Gastroenterology Society American College of Physicians American Medical Students Association, (Past President, Illinois Chap) National Crohns and Colitis Foundation Texas Medical Association

INSTRUCTION

1991- 1992-Clinical Issues in Gastroenterology: Hepatitis Interferon Therapy, UT Houston.

5, 6/91-Lecturer, The Methodist Hospital DDL Liver Block,
Baylor College of Medicine

8/88-10/88-Introduction to History and Physical, Baylor College of Medicine

8/86 10/86-Introduction to Patient: Physical Diagnosis Preceptorship, Baylor College of Medicine

.

LECTURES

4/07- HBV Advances, Obstetric Implications, Texas Women's Hospital, Houston

2/07- Novel Treatments for HCV, University of Arkansas, Little Rock

11/02- Chronic Hepatitis C Anti-Viral Therapy Adherence Techniques, CME Outreach
Texas A&M University, Corpus Christi

2002 Hepatitis Research Reviewer, Annual Meeting Hepatitis Magazine

2001-Host-Moderator, Annual Meeting Hepatitis Magazine

8/97- Combination Antiviral Therapy Developments from the NIH Consensus
Conference, Memorial Hospital Systems

10/92- Immunoprophylaxis and Therapy of Viral Hepatitis, Jefferson County Pediatric
Society

9/92 – NSAID GI Safety, Traverse County Medical Society Update, Traverse City

9/92 - Inflammatory Bowel Disease Developments, Staff Seminar, UT/St. Joseph's House

11/90 - Non-Surgical Management of Cholelithiasis, South Carolina Academy of Family
Practice, Hilton Head

8/90- Current Management of Gallstones, Louisiana Academy of Family Practice, Destin

10/88 -Non-Surgical Management of Cholelithiasis, Texas A & M School of Medicine

9/88- Biliary ESWL, Louisiana State University School of Medicine, Shreveport

6/87 - Primary Biliary Cirrhosis, Harris County Hospital (Ben Taub) Residents Forum

10/89 - Electronic Media: Interactive Computer Laser Video Disc Module for Teaching
Liver Transplant Immunosuppression, World Congress of Gastroenterology, Sydney

10/89 - Electronic Media: Interactive Computer Laser Video Disc Module for Teaching
Liver Transplant Immunosuppression, American Association for the Study of Liver
Diseases

1/88 - Interpretation of Viral Serology, Clinical Issues in Medicine, Videotape. Baylor
College of Medicine.

5/87 - The Prognostic Significance Of Soluble Interleukin-2 Receptor Levels in Human
Serum Following Orthotopic Liver Transplantation, Poster, American Gastroenterology
Association

RESEARCH PROTOCOLS

1. Adefovir Treatment of Lamivudine resistant HBV - 2002
2. PEG-Intron, Ribavirin, Amantidine HCV treatment - 2002
3. PEGASYS COPEGUS - 2002
4. Roferon Monotherapy for Chronic Hepatitis B - 1992
5. Efficacy of Nizatidine in the Maintenance of Duodenal Ulcer Healing - 1993
6. Efficacy of Nizatidine in the Maintenance of Gastric Ulcer Healing on Continued NSAID Administration - 1992
7. American Diabetes Association Grant, Histochemistry Radiology and Lipid Analysis of Steatosis in Diabetics- 1991
8. The Methodist Hospital Grant. Computer Driven Interactive Laser Video Disk Instructional Module: The Management of Transplant Immunosuppression and its Complication ". Baylor College of Medicine – 1989.
9. Treatment of Primary Biliary Cirrhosis with Oral, Pulse Methotrexate – 1989
10. A Randomized, Double Blind Trial of LdT (Telbivudine) versus Lamivudine in Adults with Compensated Chronic Hepatitis B – active.
11. A Randomized, Double Blind Trial of LdT (Telbivudine) versus Lamivudine in Adults with Decompensated Chronic Hepatitis B and Evidence of Cirrhosis – active.
12. A Randomized, Multicenter, Open Label, Phase IV Study Evaluating the Efficacy and Safety of 16-Week Versus 24 Week Treatment with PEGASYS[®] in Combination with COPEGUS[®] in Interferon-naïve patients with Chronic Hepatitis C Genotype 2 or 3 Virus Infection – 2005.
13. Study of Long Term PegIntron vs. Colchicine For Patients Who Have Failed to Respond to Rebetron/Interferon with Advanced Fibrosis and Cirrhosis Secondary to Hepatitis C Infection – active.
14. Genotype Specific Aggressive Induction Therapy in Naïve Patients – 2005.
15. Randomized, Multicenter, Double-Blind, Phase IV Pilot Study Evaluating the Effect of Pegasys Doses of 180 mcg or 270 mcg in Combination with Copegus Doses of 1200 mg or 1600 mg on Viral Kinetics, Virological Response, Pharmacokinetics, and Safety in Interferon-Naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Body Weight Greater than 85 kg – 2006.
16. A Prospective, Multicenter, Open-Label, Comparative Efficacy Study of Pegasys plus Copegus in Treatment-Naïve Latino Patients with Chronic Hepatitis C- Genotype1, as Compared to Treatment-Naïve Non-Latino Caucasian Patients with Chronic Hepatitis C- Genotype 1 – active.
17. A Randomized, Phase IIb Clinical Trial to Evaluate the Safety and Antiviral Activity of NM283 and the Combination of Pegylated Interferon plus NM283, in Patients with Chronic Hepatitis C Who have Previously Failed to Respond to Standard Therapy – 2007.
18. Comparison of PEG-Intron 1.5 mcg/kg/wk Plus REBETOL vs PEG-Intron 1 mcg/kg/wk Plus REBETOL vs PEGASYS 180 mcg/wk Plus COPEGUS in Previously Untreated Adult Subjects With Chronic Hepatitis C Infected With Genotype 1-active.
19. An Open-Label Trial of Telbivudine (LdT) in Adults with Chronic Hepatitis B

- Previously Treated in Idenix-Sponsored Telbivudine Studies – 2007.
20. A Phase 2, Randomized, Double-Blind Study Exploring the Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine plus Tenofovir DF Fixed-Dose Combination Therapy in Subjects Currently Being Treated with Adefovir Dipivoxil for Chronic Hepatitis B and having Persistent Viral Replication – 2007.
 21. A Phase 2, Double-Blind, Multi-center, Randomized Study Comparing Tenofovir Disoproxil Fumarate, Emtricitabine Plus Tenofovir Disoproxil Fumarate, and Entecavir in the Treatment of Chronic Hepatitis B Subjects with Decompensated Liver Disease and in the Prevention of Hepatitis B Recurrence Post-Transplantation – active.
 22. A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Intravenous Terlipressin in Patients with Hepatorenal Syndrome Type 1 – 2007.
 24. A Randomized, Multicenter, Double Blinded, Phase IV Study Comparing the Safety and Efficacy of Pegasys® 180µg plus Copegus® 1000 or 1200 mg to the Currently Approved Combination of Pegasys® 180µg plus Copegus® 800 mg in Interferon-naïve Patients with Chronic Hepatitis C Genotype 1 virus infection coinfecting with human immunodeficiency virus (HIV-1) – active.
 25. Validation of a Breath Test for Assessment of Liver Fibrosis in Patients with Hepatitis C Viral Infection – 2007.
 26. A phase 2, randomized, open-label study of the safety, antiviral activity, and pharmacokinetics of HCV-796 administered in combination with peg interferon alfa-2b (PEG-Intron), with or without concomitant Ribavirin (REBETOL), versus PEG-Intron plus REBETOL in subjects with hepatitis C virus genotype 1 infection – active.
 27. Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 mcg Induction Dosing of Pegasys® in Combination with Higher Copegus® Doses in Treatment-naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Baseline Body Weight Greater than or Equal to 85 kg. – active.
 28. P03523-A Safety and Efficacy Study of SCH 503034 in Previously Untreated Subjects with Chronic Hepatitis C Infected with Genotype 1 – active.
 29. A Phase 2 Study of Telaprevir (VX-950) in Combination with Peg interferon Alfa-2a (Pegasys®), and Ribavirin (Copegus®) in Subjects with Genotype 1 Hepatitis C Who Have Not Achieved Sustained Viral Response with a Prior Course of Interferon-Based Therapy. – active.
 30. A Rollover Protocol of Telaprevir (VX-950) in Combination with Peg interferon Alfa-2A (PEGASYS®) and Ribavirin (COPEGUS®) in Subjects Enrolled in the Control Group (GROUP A) of Study VX06-950-106 Who Did Not Achieve or Maintain an Undetectable HCV RNA HCV RNA Level Through Sustained Viral Response (VX06-950-107) – active.
 31. Long-Term Follow-up of Subjects in a Phase 2 or 3 Clinical Trial in Which SCH 503034 Was Administered For the Treatment of Chronic Hepatitis C – active.
 32. ML21301-Multicenter, randomized, open-label, controlled study of the effect of treatment with once weekly Pegasys® plus daily Copegus® with or without

- concomitant pioglitazone (Actos®) on early viral kinetics in treatment-naïve patients with chronic hepatitis C (genotype 1 HCV infection) and insulin resistance - active.
33. GI-5005-02 "A Phase 2 Randomized, Open Label, Multi-center, Therapeutic Trial of the Efficacy, Immunogenicity, and Safety of GI-5005; an Inactivated Recombinant *Saccharomyces cerevisiae* Expressing a Hepatitis C Virus NS3-Core Fusion Protein, Combined with Pegylated Interferon plus Ribavirin Standard of Care Therapy versus Standard of Care Alone, and GI-5005 Salvage of Standard of Care Failures, in Patients with Genotype 1 Chronic Hepatitis C Infection" – active.
 34. Clinical Study Protocol 747-202: A Study of INT-747 (6-ECDCA) in Combination with Ursodeoxycholic Acid (URSO®, UDCA) in Patients with Primary Biliary Cirrhosis – active.
 35. Clinical Study Protocol 747-201: A Study of INT 747 (6-ECDCA) Monotherapy in Patients with Primary Biliary Cirrhosis - active.
 36. CLDT600A2406 - Novartis Pharmaceuticals trial entitled: A randomized, open-label, controlled, multi-center 2-year study comparing efficacy and safety of telbivudine (LDT600) 600 mg PO in combination with peg alpha-2a 180 µg with peg alpha-2a monotherapy, and with telbivudine monotherapy in treatment naïve patients with HBeAg-positive compensated CHB. –Active.
 37. AST-120 - Comparison of Different Treatment Regimens in Patients with Stage 1 – 2 Type C Hepatic Encephalopathy AST-120 Vx. Lactulose –active.
 38. Study to Assess the Safety and Antiviral Activity of PEG-rIL-29 Administered _as a Single Agent and in Combination with Ribavirin in Subjects with Treatment-relapsed Chronic Hepatitis C Virus Infection – active.

AVOCATIONS AND COMMUNITY SERVICE

Scuba Diving, "Open Water " Certified. Tennis, Jogging, Swimming, Snorkeling, Alpine Skiing, Bicycling, Exotic Cuisine, United States Amateur Ballroom Dance Association.

First Place Finish in Hope Hop Fun Run MMA Leadership Retreat (Conroe) 11/95

US Corporate Athletic Association Team Captain Macgregor Rabbits
American Medical Athletic Association Lifetime Member Achievement Award

Finalist in Marathon (Houston) 1/15/95,96,97,98,99,2000,2001,2006,2007, 2011, 2012
and the LaSalle Marathon (Chicago) 10/15/95

PERSONAL

Married to Sheri Ratoosh, MD PhD FAAD, Dermatology
United States Citizen
Three Sons (9/13/89, 9/2/94, 9/16/98)